ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

NUCALA
Asthma/COPD
Miscellaneous immune disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

NUCALA Rx

Generic Name and Formulations:
Mepolizumab 100mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free.

Company:
GlaxoSmithKline

Therapeutic Use:

Indications for NUCALA:

Add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.

Limitations Of use:

Not for relief of acute bronchospasm or status asthmaticus.

Adult:

Give by SC inj into upper arm, thigh, or abdomen. 100mg once every 4 weeks.

Children:

Not established.

Warnings/Precautions:

Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Opportunistic infections (eg, herpes zoster); consider varicella vaccination if appropriate prior to starting therapy. Treat pre-existing helminth infections before initiating therapy; discontinue Nucala if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Nucala initiation. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Elderly. Pregnancy (monitor closely). Nursing mothers.

Pharmacological Class:

Interleukin-5 antagonist.

Adverse Reactions:

Headache, inj site reactions, back pain, fatigue; infections, hypersensitivity reactions; possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Indications for NUCALA:

Eosinophilic granulomatosis with polyangiitis (EGPA) in adults.

Adult:

Give by SC inj into upper arm, thigh, or abdomen. 300mg (as three separate 100mg inj) once every 4 weeks; inject at least 2 inches apart if at the same site.

Children:

Not established.

Warnings/Precautions:

Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Opportunistic infections (eg, herpes zoster); consider varicella vaccination if appropriate prior to starting therapy. Treat pre-existing helminth infections before initiating therapy; discontinue Nucala if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Nucala initiation. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Elderly. Pregnancy (monitor closely). Nursing mothers.

Pharmacological Class:

Interleukin-5 antagonist.

Adverse Reactions:

Headache, inj site reactions, back pain, fatigue; infections, hypersensitivity reactions; possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs